Publications by authors named "D Andreis"
Article Synopsis
- The study investigated the significance of metabolic tumor volume (tMTV) in patients with advanced non-small cell lung cancer (NSCLC) undergoing immune checkpoint blockade (ICB) therapy, using 18F-FDG-PET/CT scans.
- It involved 518 patients across multiple institutions and found that those with high tMTV had poorer overall survival when treated with ICBs alone compared to those with low tMTV.
- The research suggests that high tMTV is associated with increased systemic inflammation and genomic instability, making it a potential biomarker for determining treatment strategies in NSCLC patients with positive PD-L1 expression.
The work concerns the study of the hydrochar from digestate and hydrochar co-compost characterization as amendments. The processes for hydrochar and co-compost production were described in Part 1 of this work (Scrinzi et al., 2022).
View Article and Find Full Text PDFArticle Synopsis
- A platform called ONCO-TreC was tested in three Italian cancer centers, designed to manage oral cancer treatments and enhance communication between patients and healthcare professionals through a secure web-based system.
- The trial aimed to customize the platform, evaluate its usability, and assess its effectiveness in helping patients and healthcare professionals manage oral anticancer therapies together.
- Results revealed high adherence measurement concordance (97.3%) between the system and physician records, but discrepancies in adverse event reporting existed between patients and physicians, highlighting areas for improvement in patient engagement.
Background: The aim of this study was to improve activity over single human epidermal growth factor receptor 2 (HER2)-blockade sequential neaodjuvant regimens for HER2-positive breast cancer, by exploiting the concomitant administration of trastuzumab, taxane and anthracycline, while restraining cardiac toxicity with use of liposomal doxorubicin, and by adding metformin, based on preliminary evidence of antitumor activity.
Patients And Methods: This multi-center, single-arm, two-stage phase II trial, assessed the safety and the activity of a new treatment regimen for HER2-positive, early or locally advanced breast cancer. Patients received six 21-day cycles of non-pegylated liposomal doxorubicin, 50 mg/m intravenously (i.